On August 7, ResMed declined 6.15% overnight, trading at $209.51/share, with turnover of $4,192.1.

The decline was triggered by the company's fiscal Q4 earnings release. ResMed reported adjusted EPS of $2.95, exceeding the consensus estimate of $2.89, while revenue of $1.46 billion matched expectations, representing an 8.1% year-over-year increase. Despite the modest beat, the market focused on decelerating top-line momentum, as revenue growth has retreated from prior double-digit levels to approximately 8%, creating a notable divergence from the company's three-year EPS compound annual growth rate of 19%.

Alongside earnings, ResMed announced plans to return over $1.85 billion to shareholders in fiscal year 2027 and raised its quarterly dividend by 10% to $0.66 per share, signaling confidence in cash flow generation. However, the shareholder return commitment was insufficient to offset investor concerns regarding the growth trajectory.

ResMed is a global leader in sleep and respiratory care medical devices, specializing in CPAP equipment and cloud-based digital health applications for diagnosing, treating, and managing respiratory disorders.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)